Imatinib in Acute Ischaemic Stroke

PHASE3UnknownINTERVENTIONAL
Enrollment

1,260

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

December 31, 2022

Study Completion Date

June 30, 2023

Conditions
Acute Ischaemic Stroke
Interventions
DRUG

Imatinib 400mg

2 tablets of Imatinib 400mg per day for 6 days

DRUG

Placebo Oral Tablet

2 tablets of placebo per day for 6 days

Trial Locations (17)

28151

RECRUITING

Hässleholms sjukhus, Hässleholm

65185

RECRUITING

Centralsjukhuset Karlstad, Karlstad

90185

NOT_YET_RECRUITING

Umeå University Hospital, Umeå

633 49

NOT_YET_RECRUITING

Mälarsjukhuset Eskilstuna, Eskilstuna

413 45

RECRUITING

Sahlgrenska Universitetssjukhuset, Gothenburg

291 85

RECRUITING

Centralsjukhuset Kristianstad, Kristianstad

221 85

NOT_YET_RECRUITING

Skånes Universitetssjukhus Lund, Lund

205 02

NOT_YET_RECRUITING

Skånes Universitetssjukhus Malmö, Malmo

541 42

RECRUITING

Skaraborgs sjukhus Skövde, Skövde

112 81

RECRUITING

Capio S:t Görans Hospital, Stockholm

118 83

RECRUITING

Södersjukhuset, Stockholm

141 86

RECRUITING

Karolinska Universitetssjukhuset Huddinge, Stockholm

171 76

RECRUITING

Karolinska Universitetssjukhuset Solna, Stockholm

182 88

RECRUITING

Danderyds sjukhus, Stockholm

856 43

NOT_YET_RECRUITING

Sundsvalls Sjukhus, Sundsvall

751 85

RECRUITING

Uppsala Akademiska Sjukhus, Uppsala

721 89

RECRUITING

Västmanlands sjukhus Västerås, Västerås

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Niaz Ahmed

OTHER

NCT03639922 - Imatinib in Acute Ischaemic Stroke | Biotech Hunter | Biotech Hunter